A
Aaron M. Cook
Researcher at University of Kentucky
Publications - 79
Citations - 1294
Aaron M. Cook is an academic researcher from University of Kentucky. The author has contributed to research in topics: Subarachnoid hemorrhage & Medicine. The author has an hindex of 14, co-authored 68 publications receiving 959 citations. Previous affiliations of Aaron M. Cook include UK HealthCare.
Papers
More filters
Journal ArticleDOI
Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine.
Jennifer A. Frontera,John J. Lewin,Alejandro A. Rabinstein,Imo P. Aisiku,Anne W. Alexandrov,Anne W. Alexandrov,Aaron M. Cook,Gregory J. del Zoppo,Monisha A. Kumar,Ellinor I.B. Peerschke,Michael F. Stiefel,Jeanne Teitelbaum,Katja E. Wartenberg,Cindy L. Zerfoss +13 more
TL;DR: This guideline provides timely, evidence-based reversal strategies to assist practitioners in the care of patients with antithrombotic-associated intracranial hemorrhage.
Journal ArticleDOI
Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: Executive Summary. A Statement for Healthcare Professionals From the Neurocritical Care Society and the Society of Critical Care Medicine
Jennifer A. Frontera,John J. Lewin,Alejandro A. Rabinstein,Imo P. Aisiku,Anne W. Alexandrov,Anne W. Alexandrov,Aaron M. Cook,Gregory J. del Zoppo,Monisha A. Kumar,Ellinor I.B. Peerschke,Michael F. Stiefel,Jeanne Teitelbaum,Jeanne Teitelbaum,Katja E. Wartenberg,Cindy L. Zerfoss +14 more
TL;DR: PRELIMINARY REMARKSGuideline LimitationsPractice guidelines should be used in the context of individual patient characteristics and may be superseded by clinical judgment or patient preference.
Journal ArticleDOI
Neuroleptic Malignant Syndrome
Dominic J. Pileggi,Aaron M. Cook +1 more
TL;DR: NMS is a rare adverse drug reaction, with a complex pathophysiology and presentation, and timely diagnosis and discontinuation of antipsychotic therapy is the first-line treatment, followed by supportive care and pharmacotherapy.
Journal ArticleDOI
Factor Xa Inhibitor-Related Intracranial Hemorrhage: Results From a Multicenter, Observational Cohort Receiving Prothrombin Complex Concentrates.
TL;DR: Administration of PCCs after apixaban- and rivaroxaban-related ICH provided a high rate of excellent or good hemostasis coupled with a 3.8% thrombosis rate, and Randomized, controlled trials evaluating the clinical efficacy of P CCs in patients with factor Xa inhibitor–related I CH are needed.
Journal ArticleDOI
Predictive value of platelet reactivity unit (PRU) value for thrombotic and hemorrhagic events during flow diversion procedures: a meta-analysis.
Ebunoluwa Ajadi,Shaowli Kabir,Aaron M. Cook,Stephen Grupke,Abdulnasser Alhajeri,Justin F. Fraser +5 more
TL;DR: VerifyNow PRU values that correspond to platelet hyporesponse or hyper-response to dual antiplatelet therapy are associated with a higher risk of thrombotic and hemorrhagic events, respectively, suggesting the PRU value may offer some predictive value for these events.